Shares of Kadmon Holdings Inc (NYSE:KDMN) have received a consensus rating of “Hold” from the six ratings firms that are currently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $9.75.
KDMN has been the topic of a number of research reports. WBB Securities cut shares of Kadmon from a “hold” rating to a “sell” rating and set a $3.00 target price on the stock. in a research note on Monday, October 9th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of Kadmon in a research note on Friday, November 17th. Finally, Zacks Investment Research raised shares of Kadmon from a “sell” rating to a “hold” rating in a research note on Tuesday, November 21st.
Several institutional investors have recently modified their holdings of the stock. Wells Fargo & Company MN grew its stake in shares of Kadmon by 17.0% in the second quarter. Wells Fargo & Company MN now owns 60,033 shares of the company’s stock worth $234,000 after purchasing an additional 8,742 shares during the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of Kadmon in the second quarter worth $114,000. Bank of New York Mellon Corp bought a new stake in shares of Kadmon in the third quarter worth $119,000. Old West Investment Management LLC bought a new stake in shares of Kadmon in the third quarter worth $169,000. Finally, AE Wealth Management LLC grew its stake in shares of Kadmon by 33.6% in the third quarter. AE Wealth Management LLC now owns 323,161 shares of the company’s stock worth $1,083,000 after purchasing an additional 81,226 shares during the last quarter. 51.91% of the stock is currently owned by institutional investors.
Kadmon (NYSE KDMN) opened at $5.14 on Friday. Kadmon has a 1 year low of $2.05 and a 1 year high of $5.86.
Kadmon (NYSE:KDMN) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.04). The business had revenue of $2.28 million for the quarter, compared to analyst estimates of $5.69 million. Kadmon’s quarterly revenue was down 60.0% on a year-over-year basis. During the same period in the prior year, the company posted ($4.24) EPS. analysts expect that Kadmon will post -1.62 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Kadmon Holdings Inc (KDMN) Receives $9.75 Average PT from Brokerages” was first reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.thestockobserver.com/2018/02/05/kadmon-holdings-inc-kdmn-receives-9-75-average-pt-from-brokerages.html.
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.